Glucagon-like peptide 1 (GLP-1) receptor agonists led to a significant reduction in the risk for venous thromboembolism (VTE) among individuals with type 2 diabetes compared with dipeptidyl peptidase ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, ...
Venous thromboembolism (VTE) describes the diagnoses of deep vein thrombosis (DVT) or pulmonary embolism (PE). DVT is the formation of thrombi in the deep veins, most commonly the large veins of the ...
Potentially fatal blood clots, known as venous thromboembolism (VTE), are more likely when you’re hospitalized or part of a high-risk group. Learn how to reduce your risk. Under normal circumstances, ...
Dr. Nigel Key and Dr. Anna Falanga join us for a conversation on the updated ASCO VTE prophylaxis and treatment in patients with cancer guideline. They discuss recent evidence assessing apixaban for ...
The American College of Chest Physicians (CHEST) recently released new clinical guidelines for venous thromboembolism (VTE) management, "Antithrombotic Therapy for VTE Disease: Second Update of the ...
In patients with venous thromboembolism (VTE) who are candidates for oral anticoagulation, apixaban results in fewer hospitalizations for recurrence and less major bleeding than rivaroxaban or ...
Although acute severe ulcerative colitis (ASUC) is recognized as a life-threatening flare associated with elevated thrombotic risk, the extent and duration of hypercoagulability after hospital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results